Europe Biosimilar Market: By Molecule; By Manufacturing Type; By Indication; Regional Analysis; Historical Market and Forecast (2015-2025); Market Dynamics; Value Chain Analysis; Price Analysis; Requirements for Setting Up a Generic Drug Manufacturing Plant; Competitive Landscape; Industry Events and Developments

Europe Biosimilar Market Outlook 

The Europe biosimilar market reached a value of almost USD 2,945 million in the year 2019. The biosimilar industry is further expected to grow at a CAGR of 25% between 2020 and 2025 to reach a value of almost USD 11,234.3 million by 2025.

The Europe biosimilar market is driven by the initiatives by the European Medicines Agency (EMA). The market within the region exhibits the most mature market in the world and continues to gain momentum. The industry is further anticipated to have rapid growth in the next five years as a number of major biologics are scheduled to lose patent protection within the region. Italy was the largest biosimilars market in Europe in the year 2019.

 

Properties and Applications

Biosimilars are referred to as the biotherapeutic products, which are similar to already licensed reference biologics, on the basis of quality, safety, and efficiency. These are manufactured and approved in alignment with the stringent laws of the European Medicines Agency (EMA). The Europe biosimilar market is divided on the basis of molecule into:

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Others

On the basis of manufacturing type, the industry is divided into:

  • In-house Manufacturing
  • Contract Manufacturing

On the basis of indication, the Europe biosimilar market is segregated into:

  • Autoimmune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility

The report also covers the regional markets of biosimilar in Europe like Italy, Germany, France, the United Kingdom, Spain, and the rest of Europe.

 

Market Analysis

The Europe biosimilar market is driven by the short marketing times as launching a biosimilar does not involve extensive marketing as the security and efficacy profile of their branded counterparts has already been established. The market is further aided as the product is less expensive as compared to their branded counterparts owing to no requirement for extensive research and testing, saving both money and time; thus, reducing overall costs. Many blockbuster biologics are anticipated to lose their patent protection in this decade. The expiration of patents and other intellectual property rights is projected to generate huge opportunities for biosimilar manufacturers, further aiding the industry growth in the region over the forecast period.

A significant amount of the European population is over the age of 65 years, accounting for about one-fifth of the total population within the region. This has led to a significant increase in the burden of lifestyle diseases in Europe. The rising prevalence of diseases like oncology, autoimmune diseases, and diabetes in Europe is also expected to impel the industry growth of biosimilars during the forecast period.

 

Competitive Landscape

The report gives a detailed analysis of the following key players in the Europe biosimilar market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer Inc.
  • Celltrion Inc.
  • Novartis AG
  • Merck Sharp & Dohme Corp., 
  • Eli Lilly and Company.
  • Samsung Bioepis
  • Accord-UK Ltd.
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis. 

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Europe
    6.2    Regional
7    Industry Opportunities and Challenges
8    Europe Biosimilar Market Analysis

    8.1    Key Industry Highlights
    8.2    Europe Biosimilar Historical Market (2015-2019) 
    8.3    Europe Biosimilar Market Forecast (2020-2025)
    8.4    Europe Biosimilar Market by Molecule
    8.4.1    Infliximab
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2015-2019)
            8.4.1.3    Forecast Trend (2020-2025)
        8.4.2    Insulin Glargine
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2015-2019)
            8.4.2.3    Forecast Trend (2020-2025)
        8.4.3    Epoetin Alfa
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2015-2019)
            8.4.3.3    Forecast Trend (2020-2025)
        8.4.4    Etanercept
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2015-2019)
            8.4.4.3    Forecast Trend (2020-2025)
    8.4.5    Filgrastim
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2015-2019)
            8.4.5.3    Forecast Trend (2020-2025)
        8.4.6    Somatropin
            8.4.6.1    Market Share
            8.4.6.2    Historical Trend (2015-2019)
            8.4.6.3    Forecast Trend (2020-2025)
        8.4.7    Rituximab
            8.4.7.1    Market Share
            8.4.7.2    Historical Trend (2015-2019)
            8.4.7.3    Forecast Trend (2020-2025)
        8.4.8    Follitropin Alfa
            8.4.8.1    Market Share
            8.4.8.2    Historical Trend (2015-2019)
            8.4.8.3    Forecast Trend (2020-2025)
        8.4.9    Others
    8.5    Europe Biosimilar Market by Manufacturing Type
        8.5.1    In-house Manufacturing
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2015-2019)
            8.5.1.3    Forecast Trend (2020-2025)
        8.5.2    Contract Manufacturing
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2015-2019)
            8.5.2.3    Forecast Trend (2020-2025)
    8.6    Europe Biosimilar Market by Indication
        8.6.1    Auto-Immune Diseases
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2015-2019)
            8.6.1.3    Forecast Trend (2020-2025)
        8.6.2    Blood Disorder
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2015-2019)
            8.6.2.3    Forecast Trend (2020-2025)
        8.6.3    Diabetes
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2015-2019)
            8.6.3.3    Forecast Trend (2020-2025)
        8.6.4    Oncology
            8.6.4.1    Market Share
            8.6.4.2    Historical Trend (2015-2019)
            8.6.4.3    Forecast Trend (2020-2025)
        8.6.5    Growth Deficiency
            8.6.5.1    Market Share
            8.6.5.2    Historical Trend (2015-2019)
            8.6.5.3    Forecast Trend (2020-2025)
        8.6.6    Female Infertility
            8.6.6.1    Market Share
            8.6.6.2    Historical Trend (2015-2019)
            8.6.6.3    Forecast Trend (2020-2025)
    8.7    Europe Biosimilar Market by Country
        8.7.1    Market Share
            8.7.1.1    Italy
            8.7.1.2    Germany
            8.7.1.3    France
            8.7.1.4    United Kingdom
            8.7.1.5    Spain
            8.7.1.6    Rest of Europe
9    Regional Analysis
    9.1    Italy
        9.1.1    Historical Trend (2015-2019)
        9.1.2    Forecast Trend (2020-2025)
    9.2    Germany
        9.2.1    Historical Trend (2015-2019)
        9.2.2    Forecast Trend (2020-2025)
    9.3    France
        9.3.1    Historical Trend (2015-2019)
        9.3.2    Forecast Trend (2020-2025)
    9.4    United Kingdom
        9.4.1    Historical Trend (2015-2019)
        9.4.2    Forecast Trend (2020-2025)
    9.5    Spain
        9.5.1    Historical Trend (2015-2019)
        9.5.2    Forecast Trend (2020-2025)
    9.6    Rest of Europe
        9.6.1    Historical Trend (2015-2019)
        9.6.2    Forecast Trend (2020-2025)
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyers Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Price Analysis

    12.1    Italy Historical Price Trends (2015-2019) and Forecast (2020-2025)
    12.2    Germany Historical Price Trends (2015-2019) and Forecast (2020-2025)
    12.3    France Historical Price Trends (2015-2019) and Forecast (2020-2025)
    12.4    United Kingdom Historical Price Trends (2015-2019) and Forecast (2020-2025)
    12.5    Spain Historical Price Trends (2015-2019) and Forecast (2020-2025)
    12.6    Rest of Europe Historical Price Trends (2015-2019) and Forecast (2020-2025)
13    Requirements for Setting Up a Generic Drug Manufacturing Plant
    13.1    Manufacturing Process
    13.2    Raw Material Requirements
    13.3    Raw Material Pictures
    13.4    Land and Construction Requirements
    13.5    Machinery and Infrastructure Requirements
    13.6    Machinery Pictures
    13.7    Plant Layout
    13.8    Packaging Requirements
    13.9    Utility Requirements
    13.10    Manpower Requirements
14    Competitive Landscape
    14.1    Market Structure
    14.2    Key Players Market Share
    14.3    Company Profiles
        14.3.1    Pfizer Inc.
            14.3.1.1    Company Overview
            14.3.1.2    Product Portfolio
            14.3.1.3    Demographic Reach and Achievements
            14.3.1.4    Financial Summary
            14.3.1.5    Certifications
        14.3.2    Celltrion Inc.
            14.3.2.1    Company Overview
            14.3.2.2    Product Portfolio
            14.3.2.3    Demographic Reach and Achievements
            14.3.2.4    Financial Summary
            14.3.2.5    Certifications
        14.3.3    Novartis AG
            14.3.3.1    Company Overview
            14.3.3.2    Product Portfolio
            14.3.3.3    Demographic Reach and Achievements
            14.3.3.4    Financial Summary
            14.3.3.5    Certifications
        14.3.4    Merck Sharp & Dohme Corp., 
            14.3.4.1    Company Overview
            14.3.4.2    Product Portfolio
            14.3.4.3    Demographic Reach and Achievements
            14.3.4.4    Financial Summary
            14.3.4.5    Certifications
        14.3.5    Eli Lilly and Company.
            14.3.5.1    Company Overview
            14.3.5.2    Product Portfolio
            14.3.5.3    Demographic Reach and Achievements
            14.3.5.4    Financial Summary
            14.3.5.5    Certifications
        14.3.6    Samsung Bioepis
            14.3.6.1    Company Overview
            14.3.6.2    Product Portfolio
            14.3.6.3    Demographic Reach and Achievements
            14.3.6.4    Financial Summary
            14.3.6.5    Certifications
        14.3.7    Accord-UK Ltd.
            14.3.7.1    Company Overview
            14.3.7.2    Product Portfolio
            14.3.7.3    Demographic Reach and Achievements
            14.3.7.4    Financial Summary
            14.3.7.5    Certifications
        14.3.8    Others
15    Industrt Events and Developments

 

List of Figures and Tables

1.    Europe Biosimilar Market: Key Industry Highlights, 2015 and 2025
2.    Europe Biosimilar Historical Market: Breakup by Molecule (USD Billion), 2015-2019
3.    Europe Biosimilar Market Forecast: Breakup by Molecule (USD Billion), 2020-2025
4.    Europe Biosimilar Historical Market: Breakup by Indication (USD Billion), 2015-2019
5.    Europe Biosimilar Market Forecast: Breakup by Indication (USD Billion), 2020-2025
6.    Europe Biosimilar Historical Market: Breakup by Manufacturing Type (USD Billion), 2015-2019
7.    Europe Biosimilar Market Forecast: Breakup by Manufacturing Type (USD Billion), 2020-2025
8.    Europe Biosimilar Historical Market: Breakup by Country (USD Billion), 2015-2019
9.    Europe Biosimilar Market Forecast: Breakup by Country (USD Billion), 2020-2025
10.    Italy Historical Price Trends and Forecast 2015-2025
11.    Germany Historical Price Trends and Forecast 2015-2025
12.    France Historical Price Trends and Forecast 2015-2025
13.    United Kingdom Historical Price Trends and Forecast 2015-2025
14.    Spain Historical Price Trends and Forecast 2015-2025
15.    Rest of Europe Historical Price Trends and Forecast 2015-2025
16.    Europe Biosimilar Market Structure

Key Questions Answered in the Report

In 2019, the Europe biosimilar market attained a value of nearly USD 2,945 million.

In the forecast period of 2020-2025, the market in Europe is projected to grow at a CAGR of 25%.

By 2025, the market is estimated to reach a value of about USD 11,234.3 million.

The major drivers of the industry such the rising prevalence of diseases like autoimmune diseases and diabetes, growing geriatric population, and the lower costs of the products as compared to their branded counterparts are expected to aid the market growth.

The expected expiry of various patents is estimated to be a significant trend projected to inform the industry growth in the coming years.

The major regions in the market are Italy, Germany, France, the United Kingdom, Spain, and the rest of Europe, with Italy accounting for the largest market share.

The major molecule types in the industry are infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa, among others. 

The leading indications in the industry are autoimmune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility.

In-house manufacturing and contract manufacturing are the most significant manufacturing types in the industry.

The major players in the industry are Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company, and Samsung Bioepis, Accord-UK Ltd., among others.

Analyst Review

The Europe biosimilar market attained a value of USD 2,945 million in the year 2019 driven by the growing geriatric population in the region. Aided by the low cost of the product and the expected expiry of various patents, the market is expected to witness a further growth in the forecast period of 2020-2025, growing at a CAGR of 25%. The market is projected to reach USD 11,234.3 million by 2025.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its molecule, the biosimilar market can be segmented into infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa, among others. On the basis of indication, the industry can be segmented into autoimmune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility. In-house manufacturing and contract manufacturing are the major manufacturing types in the market. The major regional markets for biosimilar market are Italy, Germany, France, the United Kingdom, Spain, and the rest of Europe, with Italy accounting for the largest share of the market. The key players in the above industry include Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company, and Samsung Bioepis, Accord-UK Ltd., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.  

Purchase Full Report

Mini Report

$1099
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Single User License

$2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Five User License

$3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Corporate License

$4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports

Global Biosimilar Market Report and Forecast 2020-2025


NEWSLETTER